UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update

Journal of clinical medicine, 2023-10, Vol.12 (21), p.6737

2023

Volltextzugriff (PDF)

Magnetoencephalography Studies of the Envelope Following Response During Amplitude-Modulated Sweeps: Diminished Phase Synchrony in Autism Spectrum Disorder

Frontiers in human neuroscience, 2021-12, Vol.15, p.787229-787229

2021

Volltextzugriff (PDF)

Delayed M50/M100 evoked response component latency in minimally verbal/nonverbal children who have autism spectrum disorder

Molecular autism, 2019-08, Vol.10 (1), p.34-34, Article 34

2019

Volltextzugriff (PDF)

Acquired Pure Red Cell Aplasia Associated with Chronic Myelomonocytic Leukemia: Too Many of One, Not Enough of the Other

Case reports in oncology, 2020-10, Vol.13 (3), p.1270-1274

2020

Volltextzugriff (PDF)

Maturation of auditory neural processes in autism spectrum disorder - A longitudinal MEG study

NeuroImage clinical, 2016-01, Vol.11 (C), p.566-577

2016

Volltextzugriff (PDF)

Delayed Auditory Evoked Responses in Autism Spectrum Disorder across the Life Span

Developmental neuroscience, 2019-01, Vol.41 (3-4), p.223-233

2019

Volltextzugriff (PDF)

Multimodal Diffusion-MRI and MEG Assessment of Auditory and Language System Development in Autism Spectrum Disorder

Frontiers in neuroanatomy, 2016-03, Vol.10, p.30-30

2016

Volltextzugriff (PDF)

Quantitative proteomics analysis by isobaric tags for relative and absolute quantitation identified Lumican as a potential marker for acute aortic dissection

BioMed research international, 2011-01, Vol.2011 (1), p.920763

2011

Volltextzugriff (PDF)

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

The lancet oncology, 2022-08, Vol.23 (8), p.1055-1065

2022

Volltextzugriff (PDF)

An extended release ciprofloxacin/dexamethasone hydrogel for otitis media

International journal of pediatric otorhinolaryngology, 2020-11, Vol.138, p.110311-110311, Article 110311

2020

Volltextzugriff (PDF)

PO-05-178 DECIPHERING THERAPEUTIC RESCUE PATTERNS FOR LONG QT SYNDROME: A COMPREHENSIVE ANALYSIS OF KCNH2 MISSENSE VARIANTS AND THEIR RESPONSE TO CHAPERONE THERAPEUTICS

Heart rhythm, 2024-05, Vol.21 (5), p.S575-S575

2024

Volltextzugriff (PDF)

Toxicity associated with high-dose intravenous methotrexate for hematological malignancies

Leukemia & lymphoma, 2022-08, Vol.63 (10), p.2375-2382

2022

Volltextzugriff (PDF)

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Blood, 2023-11, Vol.142 (Supplement 1), p.614-614

2023

Volltextzugriff (PDF)

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

Clinical cancer research, 2022-09, Vol.28 (18), p.4003-4017

2022

Volltextzugriff (PDF)

Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab

Blood reviews, 2017-01, Vol.31 (1), p.23-35

2017

Volltextzugriff (PDF)

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Blood, 2023-11, Vol.142 (Supplement 1), p.603-603

2023

Volltextzugriff (PDF)

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Blood, 2022-11, Vol.140 (Supplement 1), p.9413-9415

2022

Volltextzugriff (PDF)

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood, 2022-11, Vol.140 (Supplement 1), p.3728-3730

2022

Volltextzugriff (PDF)

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Blood, 2022-11, Vol.140 (Supplement 1), p.1467-1470

2022

Volltextzugriff (PDF)

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Blood, 2021-11, Vol.138 (Supplement 1), p.2436-2436

2021

Volltextzugriff (PDF)

Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study

Blood, 2021-11, Vol.138 (Supplement 1), p.1456-1456

2021

Volltextzugriff (PDF)

1 – 25 von 273

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(234)
Mit Volltextzugriff
(230)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(273)
Japanisch
(42)

Erscheinungsjahr

n.n

Thema

Science & Technology
(184)
Life Sciences & Biomedicine
(130)
Humans
(77)
Animals
(33)
Technology
(33)
Male
(31)
Physical Sciences
(29)
Female
(27)
Oncology
(22)
Mice
(21)
Adult
(19)
Materials Science
(18)
Materials Science, Multidisciplinary
(18)
Neurosciences & Neurology
(17)
Physics
(17)
Patients
(15)
Science & Technology - Other Topics
(15)
Middle Aged
(14)
Neurosciences
(14)
Social Sciences
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(32)
American Journal Of Kidney Diseases
(10)
Clinical Cancer Research
(8)
Cancer Research
(5)
Leukemia & Lymphoma
(4)
Materials Science Forum
(4)
Nature Communications
(4)
Cancers
(3)
Chemistry Of Materials
(3)
Health Affairs
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update

Magnetoencephalography Studies of the Envelope Following Response During Amplitude-Modulated Sweeps: Diminished Phase Synchrony in Autism Spectrum Disorder

Delayed M50/M100 evoked response component latency in minimally verbal/nonverbal children who have autism spectrum disorder

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance

Acquired Pure Red Cell Aplasia Associated with Chronic Myelomonocytic Leukemia: Too Many of One, Not Enough of the Other

Maturation of auditory neural processes in autism spectrum disorder - A longitudinal MEG study

Delayed Auditory Evoked Responses in Autism Spectrum Disorder across the Life Span

Multimodal Diffusion-MRI and MEG Assessment of Auditory and Language System Development in Autism Spectrum Disorder

Quantitative proteomics analysis by isobaric tags for relative and absolute quantitation identified Lumican as a potential marker for acute aortic dissection

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

An extended release ciprofloxacin/dexamethasone hydrogel for otitis media

PO-05-178 DECIPHERING THERAPEUTIC RESCUE PATTERNS FOR LONG QT SYNDROME: A COMPREHENSIVE ANALYSIS OF KCNH2 MISSENSE VARIANTS AND THEIR RESPONSE TO CHAPERONE THERAPEUTICS

Toxicity associated with high-dose intravenous methotrexate for hematological malignancies

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study

Aktive Filter

Suchergebnisse filtern